|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded |
Company Size: |
10-19 Employees In BC (10-19 Total)
10-19 In BC (10-19 Total)
|
Year Founded: |
2017 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
NervGen Pharma Corp.
|
|
|
|
NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing treatments for patients suffering from medical conditions related to nerve damage, either as a result of injury, neurodegenerative disease, or other causes. |
|
|
Date |
Type |
Amount |
Investors |
Jul 18, 2022 |
Private Placement |
$15 Million USD |
|
Jun 30, 2022 |
Private Placement |
$15 Million USD |
|
Nov 14, 2021 |
Private Placement |
$9.2 Million CAD |
|
Date |
Type |
Amount |
Investors |
Jul 18, 2022 |
Private Placement |
$15M USD |
|
Jun 30, 2022 |
Private Placement |
$15M USD |
|
Nov 14, 2021 |
Private Placement |
$9.2M CAD |
|
|
|
|
Want More NervGen Pharma Corp. News? 1 2
|
Next »
|
|
|
|
|
|
|
Apr 20, 2023
|
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer
|
|
Apr 5, 2023
|
NervGen Pharma Reports 2022 Year End Results And Provides Operational Update
|
|
Dec 13, 2022
|
NervGen Pharma Completes Dosing in Its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results
|
|
Nov 29, 2022
|
NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Office
|
|
Nov 9, 2022
|
NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291
|
|
Oct 13, 2022
|
NervGen Pharma Awarded up to US $1.5 Million in Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury
|
|
Sep 23, 2022
|
NervGen Pharma Announces Leadership Transition
|
|
Sep 19, 2022
|
NervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Development
|
|
Aug 3, 2022
|
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Preclinical Study
|
|
Jul 19, 2022
|
NervGen Pharma Closes $19.5 Million Private Placement Financing, and Appoints Dr. Adam Rogers to Board of Directors
|
|
|
1 - 10 of 20 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
